- 抑制劑
- 化合物庫
- 抗體
- 生物試劑
- qPCR
- 2x SYBR Green qPCR Master Mix
- 2x SYBR Green qPCR Master Mix(Low ROX)
- 2x SYBR Green qPCR Master Mix(High ROX)
- 蛋白實驗
- Protein A/G免疫沉淀磁珠
- Anti-DYKDDDDK Tag免疫磁珠
- Anti-DYKDDDDK Tag親和凝膠
- Anti-Myc免疫磁珠
- Anti-HA免疫磁珠
- 磁力架
- Poly DYKDDDDK Tag多肽
- 細胞核與細胞漿蛋白抽提試劑盒
- 免疫磁珠
- 蛋白酶抑制劑Cocktail
- 蛋白酶抑制劑Cocktail(DMSO儲液)
- 磷酸酶抑制劑Cocktail
- 新產品
- 聯(lián)系我們
Home
DNA Damage/DNA Repair
Antineoplastic and Immunosuppressive Antibiotics activator
-
DNA/RNA Synthesis inhibitor
-
Autophagy activator
Actinomycin D (Dactinomycin)
僅限科研使用
Actinomycin D (Dactinomycin)
別名: Act D, RASP-101 中文名稱：放線菌素D, 更生霉素
此產品請避光密封保存。
Actinomycin D (Dactinomycin, Act D, RASP-101)是一種從鏈霉菌屬的土壤細菌中分離出來的重要的多肽抗生素。Actinomycin D (Dactinomycin) 可抑制 DNA repair，并使 cell cycle 停滯在G1期，其IC50值分別為0.42 μM和0.4 nM。Actinomycin D 是一種 RNA和蛋白質合成抑制劑，能夠抑制細菌的蛋白合成。Actinomycin D (Dactinomycin) 是 autophagy 的激活劑，可在高危慢性淋巴細胞性白血病中誘導p53依賴性細胞的死亡并延長生存期。此產品為危化品（急性毒性/易燃/皮膚腐蝕），請在穿戴防護面罩、防護手套和防護服后使用。 已取得危險化學品經營許可
Actinomycin D (Dactinomycin) Chemical Structure
CAS: 50-76-0
產品質控
批次：
純度：
99.74%
99.74
Actinomycin D (Dactinomycin)相關產品
細胞實驗數(shù)據(jù)示例
| 細胞系 | 實驗類型 | 給藥濃度 | 孵育時間 | 活性描述 | 文獻信息(PMID) |
|---|---|---|---|---|---|
| NCI-H157 | Apoptosis assay | 10 uM | 5 hrs | Induction of apoptosis in human NCI-H157 cells assessed as live cell level at 10 uM incubated for 5 hrs in serum-free medium by annexin V/propidium iodide staining by flow cytometry | 22863528 |
| HeLa | Cytotoxicity assay | 1 uM | 18 hrs | Cytotoxicity against human HeLa cells assessed as reduction in cell viability at 1 uM after 18 hrs by inverse MTT assay | 25028062 |
| A549 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by alamar blue assay, EC50 = 0.000201 μM. | 27736087 | |
| PC3 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by alamar blue assay, EC50 = 0.000276 μM. | 27736087 | |
| L1210 | Function assay | 3 hrs | Inhibition of RNA synthesis in mouse L1210 cells assessed as [3H]-uridine incorporation preincubated for 3 hrs before [3H]-uridine addition measured after 1 hr by scintillation spectrometric analysis, ED50 = 0.009 μM. | 330857 | |
| L1210 | Function assay | 3 hrs | Inhibition of DNA synthesis in mouse L1210 cells assessed as [3H]-thymidine incorporation preincubated for 3 hrs before [3H]-thymidine addition measured after 1 hr by scintillation spectrometric analysis, ED50 = 0.4 μM. | 330857 | |
| HMO2 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human HMO2 cells after 48 hrs by sulforhodamine assay, GI50 = 0.3 μM. | 10757717 | |
| MCF7 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine assay, GI50 = 0.5 μM. | 10757717 | |
| HepG2 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human HepG2 cells after 48 hrs by sulforhodamine assay, GI50 = 1 μM. | 10757717 | |
| P388 | Antiproliferative assay | 48 hrs | Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay, IC50 = 0.0002 μM. | 2778449 | |
| HT-29 | Antiproliferative assay | 96 hrs | Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay, IC50 = 0.223 μM. | 2778449 | |
| Jurkat T | Function assay | 48 hrs | Inhibitory concentration was evaluated on human Jurkat T-cells after their exposure for 48 hours, IC50 = 0.0045 μM. | 11052798 | |
| HeLa | Cytotoxicity assay | 48 hrs | Cytotoxicity against human HeLa cells in log-phase after 48 hrs by MTT assay, IC50 = 0.001 μM. | 16309323 | |
| Vero | Cytotoxicity assay | 48 hrs | Cytotoxicity against african green monkey Vero cells in log-phase after 48 hrs by MTT assay, IC50 = 0.001 μM. | 16309323 | |
| Hep2 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human Hep2 cells in log-phase after 48 hrs by MTT assay, IC50 = 0.006 μM. | 16309323 | |
| HeLa | Cytotoxicity assay | 48 hrs | Cytotoxicity against human HeLa cells in lag-phase after 48 hrs by MTT assay, IC50 = 0.011 μM. | 16309323 | |
| Vero | Cytotoxicity assay | 48 hrs | Cytotoxicity against african green monkey Vero cells in lag-phase after 48 hrs by MTT assay, IC50 = 0.071 μM. | 16309323 | |
| Hep2 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human Hep2 cells in lag-phase after 48 hrs by MTT assay, IC50 = 0.191 μM. | 16309323 | |
| CCRF-CEM | Cytotoxicity assay | 72 hrs | Cytotoxicity against human CCRF-CEM cells after 72 hrs, IC50 = 0.0016 μM. | 18329887 | |
| HeLa | Antiproliferative assay | 48 hrs | Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay, IC50 = 0.0004 μM. | 18461997 | |
| HT29 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human HT29 cells after 48 hrs by MTT assay, IC50 = 0.0029 μM. | 18461997 | |
| U2OS | Antiproliferative assay | 48 hrs | Antiproliferative activity against human U2OS cells after 48 hrs by MTT assay, IC50 = 0.0032 μM. | 18461997 | |
| HeLa | Function assay | 2 hrs | Inhibition of transcriptional activity in human HeLa cells assessed as [3H]uridine utilization after 2 hrs by scintillation counting, IC50 = 0.2624 μM. | 20118940 | |
| HeLa | Function assay | 2 hrs | Inhibition of protein synthesis in human HeLa cells assessed as [35S]cysteine/methionine utilization after 2 hrs by scintillation spectroscopy, IC50 = 0.5197 μM. | 20118940 | |
| NCI-H460 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human NCI-H460 cells after 72 hrs by MTS reduction assay, IC50 = 0.008 μM. | 20704331 | |
| SF268 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human SF268 cells after 72 hrs by MTS reduction assay, IC50 = 0.016 μM. | 20704331 | |
| MCF7 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human MCF7 cells after 72 hrs by MTS reduction assay, IC50 = 0.103 μM. | 20704331 | |
| Vero | Cytotoxicity assay | 20 hrs | Cytotoxicity against african green monkey Vero cells after 20 hrs by MTS assay, IC50 = 11 μM. | 21093966 | |
| HeLa | Cytotoxicity assay | 48 hrs | Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay, IC50 = 0.0011 μM. | 22705001 | |
| A549 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay, IC50 = 0.0072 μM. | 22705001 | |
| MCF7 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay, IC50 = 0.024 μM. | 22705001 | |
| Vero | Cytotoxicity assay | 48 hrs | Cytotoxicity against african green monkey Vero cells assessed as cell viability after 48 hrs by MTT assay, IC50 = 0.071 μM. | 22705001 | |
| HeLa | Cytotoxicity assay | 48 hrs | Cytotoxicity against human HeLa cells in lag phase of growth after 48 hrs, IC50 = 0.0011 μM. | 24709561 | |
| HeLa | Cytotoxicity assay | 48 hrs | Cytotoxicity against human HeLa cells in log phase of growth after 48 hrs, IC50 = 0.0016 μM. | 24709561 | |
| Hep2 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human Hep2 cells in log phase of growth after 48 hrs, IC50 = 0.0062 μM. | 24709561 | |
| Vero | Cytotoxicity assay | 48 hrs | Cytotoxicity against African green monkey Vero cells in log phase of growth after 48 hrs, IC50 = 0.01 μM. | 24709561 | |
| Vero | Cytotoxicity assay | 48 hrs | Cytotoxicity against African green monkey Vero cells in lag phase of growth after 48 hrs, IC50 = 0.072 μM. | 24709561 | |
| Hep2 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human Hep2 cells in lag phase of growth after 48 hrs, IC50 = 0.17 μM. | 24709561 | |
| HEK293 | Function assay | 30 mins | Inhibition of human DDR2 expressed in HEK293 cells assessed as reduction in collagen-1-induced DDR2 tyrosine phosphorylation pre-incubated for 30 mins by immunoblotting method, IC50 = 9 μM. | 25569119 | |
| HeLa | Cytotoxicity assay | 48 hrs | Cytotoxicity against human HeLa cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay, IC50 = 0.0011 μM. | 28923386 | |
| A549 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human A549 cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay, IC50 = 0.0072 μM. | 28923386 | |
| Vero | Cytotoxicity assay | 48 hrs | Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay, IC50 = 0.011 μM. | 28923386 | |
| MCF7 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MCF7 cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay, IC50 = 0.024 μM. | 28923386 | |
| Vero | Cytotoxicity assay | 48 hrs | Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay, IC50 = 0.071 μM. | 28923386 | |
| A2780 | Cytotoxicity assay | Cytotoxicity against human A2780 cells, Activity = 0.0017 μM. | 16562838 | ||
| L1210 | Function assay | Inhibition of RNA synthesis in mouse L1210 cells by [3H]-uridine incorporation assay, ED50 = 0.015 μM. | 573799 | ||
| L1210 | Function assay | Inhibition of DNA synthesis in mouse L1210 cells by [3H]-thymidine incorporation assay, ED50 = 0.6 μM. | 573799 | ||
| P388 | Function assay | Concentration required for 50% inhibition of incorporation of labeled uridine by P388 cells for the synthesis of RNA (in vitro), ED50 = 0.046 μM. | 6169834 | ||
| P388 | Function assay | Concentration required for 50% inhibition of incorporation of labeled thymidine by p388 cells for synthesis of DNA (in vitro), ED50 = 0.996 μM. | 6169834 | ||
| B104-1-1 | Growth inhibitory assay | Growth inhibitory activity was tested against B104-1-1 cells, GI50 = 0.0007 μM. | 10888331 | ||
| Hep G2 | Cytotoxicity assay | Cytotoxicity against human Hep G2 cells, GI50 = 0.0012 μM. | 16933866 | ||
| HM02 | Cytotoxicity assay | Cytotoxicity against human HM02 cells, GI50 = 0.0016 μM. | 16933866 | ||
| L1210 | Function assay | Inhibition of synthesis of [5-3H]-uridine into RNA in L1210 cells., IC50 = 0.019 μM. | 3397991 | ||
| L1210 | Function assay | Inhibition of synthesis of [methyl-14C] thymidine into DNA, in L1210 cells., IC50 = 0.38 μM. | 3397991 | ||
| Jurkat T | Function assay | Inhibitory concentration against Human Jurkat T cells, IC50 = 0.0045 μM. | 10212121 | ||
| B104-1-1 | Function assay | In vitro binding assay of Shc-derived phosphopeptide to Growth factor receptor bound protein 2 SH2 in B104-1-1 cells was determined, IC50 = 5 μM. | 10888331 | ||
| C8166 | Antitumor assay | Antitumor activity against CD+ human acute T-lymphoblastic leukemia C8166 cells, IC50 = 0.0008 μM. | 12431048 | ||
| CCRF-CEM | Antitumor assay | Antitumor activity against human acute T-lymphoblastic leukemia CCRF-CEM cells, IC50 = 0.001 μM. | 12431048 | ||
| CD4+T | Antitumor assay | Antitumor activity against human CD4+T cells expressing the TAT gene of HTLV-1 MT-4 cells, IC50 = 0.001 μM. | 12431048 | ||
| MOLT-4 | Antitumor assay | Antitumor activity against human acute T-lymphoblastic leukemia MOLT-4 cells, IC50 = 0.001 μM. | 12431048 | ||
| G-361 | Antitumor assay | Antitumor activity against human skin melanoma G-361 cells, IC50 = 0.001 μM. | 12431048 | ||
| MT-4 | Antitumor assay | Antitumor activity against CD+ human acute T-lymphoblastic leukemia MT-4 cells, IC50 = 0.001 μM. | 12431048 | ||
| CCRF-SB | Antitumor assay | Antitumor activity against human acute B-lymphoblastic leukemia CCRF-SB cells, IC50 = 0.002 μM. | 12431048 | ||
| SKMEK-28 | Antitumor assay | Antitumor activity against human skin melanoma SKMEK-28 cells, IC50 = 0.002 μM. | 12431048 | ||
| Raji | Antitumor assay | Antitumor activity against human Burkitt lym phoma Raji cells, IC50 = 0.002 μM. | 12431048 | ||
| 5637 | Antitumor assay | Antitumor activity against human bladder carcinoma 5637 cells, IC50 = 0.003 μM. | 12431048 | ||
| Wil2-NS | Antitumor assay | Anti tumor activity against human splenic B-lympho blastoid Wil2-NS cells, IC50 = 0.003 μM. | 12431048 | ||
| Hep-2 | Antitumor assay | Antitumor activity against larynx carcinoma Hep-2 cells, IC50 = 0.004 μM. | 12431048 | ||
| SK-MES-1 | Antitumor assay | Antitumor activity against human lung squamous carcinoma SK-MES-1 cells, IC50 = 0.004 μM. | 12431048 | ||
| ACHN | Antitumor assay | Antitumor activity against human renal adenocarcinoma ACHN cells, IC50 = 0.005 μM. | 12431048 | ||
| KB | Function assay | Compound concentration required to reduce the cell proliferation of Wild type and Drug- resistant human nasopharyngeal carcinoma KB cells by 50%, IC50 = 0.005 μM. | 12431048 | ||
| HT-29 | Antitumor assay | Antitumor activity against human colon adenocarcinoma HT-29 cells, IC50 = 0.006 μM. | 12431048 | ||
| MCF-7 | Antitumor assay | Antitumor activity against human breast adenocarcinoma MCF-7 cells, IC50 = 0.006 μM. | 12431048 | ||
| CRL7065 | Antitumor assay | Antitumor activity against human foreskin fibroblasts CRL7065 cells, IC50 = 0.007 μM. | 12431048 | ||
| DU145 | Antitumor assay | Antitumor activity against human prostate carcinoma DU145 cells, IC50 = 0.008 μM. | 12431048 | ||
| Hela | Antitumor assay | Antitumor activity against cervix carcinoma Hela cells cells, IC50 = 0.008 μM. | 12431048 | ||
| HepG2 | Antitumor assay | Antitumor activity against human hepatocellular carcinoma HepG2 cells, IC50 = 0.01 μM. | 12431048 | ||
| C8166 | Antitumor assay | Antitumor activity against CD4+ human acute T-lymphoblastic C8166 leukemia cells., IC50 = 0.00008 μM. | 12431049 | ||
| MT-4 | Antitumor assay | Antitumor activity against CD4+ human acute T-lymphoblastic MT-4 leukemia cells., IC50 = 0.0009 μM. | 12431049 | ||
| G361 | Antitumor assay | Antitumor activity against human skin melanoma G361 cells., IC50 = 0.001 μM. | 12431049 | ||
| MOLT-4 | Antitumor assay | Antitumor activity against human acute T-lymphoblastic MOLT-4 leukemia cells., IC50 = 0.001 μM. | 12431049 | ||
| CCRF-SB | Antitumor assay | Antitumor activity against human acute B-lymphoblastic CCRF-SB leukemia cells., IC50 = 0.001 μM. | 12431049 | ||
| Raji | Antitumor assay | Antitumor activity against human Burkitt lymphoma Raji cells., IC50 = 0.002 μM. | 12431049 | ||
| 5637 | Antitumor assay | Antitumor activity against human bladder carcinoma 5637 cells., IC50 = 0.003 μM. | 12431049 | ||
| CCRF-CEM | Antitumor assay | Antitumor activity against human acute T-lymphoblastic CCRF-CEM leukemia cells., IC50 = 0.003 μM. | 12431049 | ||
| Wil-NS | Antitumor assay | Antitumor activity against human splenic B-lymphoblastoid Wil-NS cells., IC50 = 0.003 μM. | 12431049 | ||
| Hep-2 | Antitumor assay | Antitumor activity against Hep-2 larynx carcinoma cells., IC50 = 0.004 μM. | 12431049 | ||
| ACHN | Antitumor assay | Antitumor activity against human renal adenocarcinoma ACHN cells., IC50 = 0.005 μM. | 12431049 | ||
| MCF-7 | Antitumor assay | Antitumor activity against human breast adenocarcinoma MCF-7 cells., IC50 = 0.006 μM. | 12431049 | ||
| HT-29 | Antitumor assay | Antitumor activity against human colon adenocarcinoma HT-29 cells., IC50 = 0.006 μM. | 12431049 | ||
| HepG-2 | Antitumor assay | Antitumor activity against human hepatocellular carcinoma HepG-2 cells., IC50 = 0.01 μM. | 12431049 | ||
| HeLa | Antitumor assay | Antitumor activity against HeLa cervical carcinoma cells., IC50 = 0.04 μM. | 12431049 | ||
| CCRF-CEM | Cytotoxicity assay | Cytotoxicity in human leukemic CCRF-CEM cells., IC50 = 1.6 μM. | 14667232 | ||
| A2780 | Cytotoxicity assay | Cytotoxicity against human A2780 cells, IC50 = 0.0008 μM. | 15844934 | ||
| A2780 | Cytotoxicity assay | Cytotoxicity against human A2780 cells, IC50 = 0.0008 μM. | 16180816 | ||
| MOLT3 | Cytotoxicity assay | Cytotoxicity against MOLT3 Leukemia cells by MTS assay, IC50 = 1 μM. | 16420056 | ||
| U937 | Cytotoxicity assay | Cytotoxicity against U937 Lymphoma cells by MTS assay, IC50 = 1 μM. | 16420056 | ||
| Vero | Cytotoxicity assay | Cytotoxicity against normal vero kidney cells by MTS assay, IC50 = 11 μM. | 16420056 | ||
| Wil2-NS | Antiproliferative assay | Antiproliferative activity against human Wil2-NS cells by MTT assay, IC50 = 0.003 μM. | 16913700 | ||
| HeLa | Antiproliferative assay | Antiproliferative activity against human HeLa cells by MTT assay, IC50 = 0.04 μM. | 16913700 | ||
| B16 | Growth inhibition assay | In vitro 50% Growth inhibition of sensitive B16 cells., ID50 = 0.003 μM. | 3397991 | ||
| L1210 | Growth inhibition assay | 50% Inhibition of growth of L1210 cells in culture., ID50 = 0.0601 μM. | 3397991 | ||
| P388/ADR | Growth inhibition assay | In vitro 50% Growth inhibition of actinomycin resistant P388/ADR cells, ID50 = 2.5 μM. | 3397991 | ||
| HeLa | Apoptosis assay | Induction of apoptosis in human HeLa cells assessed as DNA fragmentation by agarose gel electrophoresis | 22705001 | ||
| TC32 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 29435139 | ||
| U-2 OS | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 29435139 | ||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 29435139 | ||
| DAOY | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 29435139 | ||
| Saos-2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 29435139 | ||
| BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 29435139 | ||
| RD | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 29435139 | ||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 29435139 | ||
| BT-12 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 29435139 | ||
| MG 63 (6-TG R) | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 29435139 | ||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 29435139 | ||
| BT-12 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells | 29435139 | ||
| LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells | 29435139 | ||
| DAOY | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells | 29435139 | ||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells | 29435139 | ||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) | 29435139 | ||
| BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells | 29435139 | ||
| MG 63 (6-TG R) | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells | 29435139 | ||
| U-2 OS | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells | 29435139 | ||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells | 29435139 | ||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SK-N-SH cells | 29435139 | ||
| Rh41 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells | 29435139 | ||
| Daoy | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for Daoy cells | 29435139 | ||
| TC32 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for TC32 cells | 29435139 | ||
| MG 63 (6-TG R) | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for MG 63 (6-TG R) cells | 29435139 | ||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | ||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells | 29435139 | ||
| SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells | 29435139 | ||
| TC32 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells | 29435139 | ||
| SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SJ-GBM2 cells | 29435139 | ||
| RD | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for RD cells | 29435139 | ||
| 點擊查看更多細胞系數(shù)據(jù) | |||||
生物活性
| 產品描述 | Actinomycin D (Dactinomycin, Act D, RASP-101)是一種從鏈霉菌屬的土壤細菌中分離出來的重要的多肽抗生素。Actinomycin D (Dactinomycin) 可抑制 DNA repair，并使 cell cycle 停滯在G1期，其IC50值分別為0.42 μM和0.4 nM。Actinomycin D 是一種 RNA和蛋白質合成抑制劑，能夠抑制細菌的蛋白合成。Actinomycin D (Dactinomycin) 是 autophagy 的激活劑，可在高危慢性淋巴細胞性白血病中誘導p53依賴性細胞的死亡并延長生存期。此產品為危化品（急性毒性/易燃/皮膚腐蝕），請在穿戴防護面罩、防護手套和防護服后使用。 | ||||||
|---|---|---|---|---|---|---|---|
| 靶點 |
|
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06252285 | Recruiting | RSV Immunisation |
Sanofi Pasteur a Sanofi Company|Sanofi |
February 6 2024 | Phase 3 |
| NCT05858723 | Not yet recruiting | Allergic Contact Dermatitis |
National Allergy Research Center Denmark |
August 2023 | Not Applicable |
|
化學信息&溶解度
| 分子量 | 1255.42 | 分子式 | C62H86N12O16 |
| CAS號 | 50-76-0 | SDF | -- |
| 儲存條件(自收到貨起) | 3年 -20°C(避光) 粉狀 | ||
|
體外溶解度 |
DMSO : 100 mg/mL ( (79.65 mM) ；DMSO吸濕會降低化合物溶解度，請使用新開封DMSO) Water : Insoluble Ethanol : Insoluble |
摩爾濃度計算器 |
|
體內溶解配方 現(xiàn)配現(xiàn)用，請按從左到右的順序依次添加，澄清后再加入下一溶劑 |
動物體內配方計算器 | |||||
實驗計算
動物體內配方計算器（澄清溶液）
第一步：請輸入基本實驗信息（考慮到實驗過程中的損耗，建議多配一只動物的藥量）
mg/kg
g
μL
只
第二步：請輸入動物體內配方組成（配方適用于不溶于水的藥物；不同批次藥物配方比例不同，請聯(lián)系Selleck為您提供正確的澄清溶液配方）
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
計算結果：
工作液濃度： mg/ml；
DMSO母液配制方法： mg 藥物溶于μL DMSO溶液（母液濃度mg/mL，注：如該濃度超過該批次藥物DMSO溶解度，請先聯(lián)系Selleck）；
體內配方配制方法：取μL DMSO母液，加入μL PEG300，混勻澄清后加入μL Tween 80，混勻澄清后加入μL ddH2O，混勻澄清。
體內配方配制方法：取μL DMSO母液，加入μL Corn oil，混勻澄清。
注意：1. 首先保證母液是澄清的；
2.一定要按照順序依次將溶劑加入，進行下一步操作之前必須保證上一步操作得到的是澄清的溶液，可采用渦旋、超聲或水浴加熱等物理方法助溶。
技術支持
在訂購、運輸、儲存和使用我們的產品的任何階段，您遇到的任何問題，均可以通過撥打我們的熱線電話400-668-6834，或者技術支持郵箱[email protected]，直接聯(lián)系到我們。我們會在24小時內盡快聯(lián)系您。
如果有其他問題，請給我們留言。
* 必填項
